首页 | 本学科首页   官方微博 | 高级检索  
检索        

流式细胞术检测微小残留病变在急性白血病造血干细胞移植中的应用
引用本文:施晓兰,唐晓文,吴德沛,孙爱宁,王荧,朱明清.流式细胞术检测微小残留病变在急性白血病造血干细胞移植中的应用[J].苏州大学学报(自然科学版),2010,30(3):517-520.
作者姓名:施晓兰  唐晓文  吴德沛  孙爱宁  王荧  朱明清
作者单位:苏州大学附属第一医院血液科,江苏省血液研究所,卫生部血栓与止血重点实验室,江苏苏州,215006
基金项目:江苏省"科教兴卫"工程医学重点人才资助项目,江苏省人事厅"六大人才高峰"资助项目,苏州市国际科技合作项目,苏州市科技计划应用摹础项目
摘    要:目的探讨流式细胞术(FCM)检测微小残留病变(MRD)在急性白血病(AL)造血干细胞移植(HSCT)中的应用。方法采用以CD45与侧向散射光(CD45/SSC)设门的三色及四色荧光标记流式细胞术检测114例AL患者移植前后的MRD水平,回顾性分析MRD与预后的关系。结果移植前MRD高于10-4尤其是高于10-3者和移植后MRD持续高于10-3者移植后复发率明显增高,移植前MRD高于10-3者其无事件生存率和无复发生存率明显低下(均P〈0.05)。首次检出MRD高于10-3的时间比临床诊断复发提前3个月。结论采用FCM动态监测AL患者HSCT前后的MRD水平,可有效评估患者预后,从而指导临床早期干预性治疗,降低移植后复发率。

关 键 词:微小残留病变  急性白血病  造血干细胞移植  流式细胞术

Application of Flow Cytometry in Detection of Minimal Residual Disease in Hematopoietic Stem Cell Transplantation for Patients with Acute Leukemia
SHI Xiao-lan,TANG Xiao-wen,WU De-pei,SUN Ai-ning,WANG Ying,ZHU Ming-qing.Application of Flow Cytometry in Detection of Minimal Residual Disease in Hematopoietic Stem Cell Transplantation for Patients with Acute Leukemia[J].Suzhou University Journal of Medical Science,2010,30(3):517-520.
Authors:SHI Xiao-lan  TANG Xiao-wen  WU De-pei  SUN Ai-ning  WANG Ying  ZHU Ming-qing
Institution:(Dept of Hematology,the First Hospital Affiliated to Soochow University,Jiangsu Institute of Hematology,Key Laboratory of Thrombosis and Hemostasis,Ministry of Health,Jiangsu Suzhou 215006,China)
Abstract:Objective To explore the relation between the outcome of patients with acute leukemia(AL) and the level of minimal residual disease by flow cytometry(FCM) in hematopoietic stem cell transplantation(HSCT).Method With the use of three or four-color FCM(CD45/SSC gating) to detect minimal residual disease(MRD),we retrospectively analyzed the MRD levels and prognosis of one hundred and fourteen AL patients before and after HSCT.Results Patients whose MRD levels were 10 -4 especially 10 -3 pre-HSCT and continuously 10 -3 post-HSCT had higher incidence of relapse.Patients with MRD levels 10 -3 pre-HSCT presented higher relapse rate and lower three-years event-free survival,relapse-free survival(all P 0.05).The median time from high level MRD detected 10 -3 first time to clinical relapse was 3 months.Patients with MRD more than 10 -3 detected successively preand post-HSCT took more chance to relapse than other groups.Conclusion This study indicates that MRD should be detected dynamically with FCM,both pre-and post-HSCT,for patients with AL undergoing HSCT to provide information for clinical intervention therapy in order to reduce the relapse rate.
Keywords:minimal residual disease  acute leukemia  hematopoietic stem cell transplantation  flow cytometry
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号